TNYA Tenaya Therapeutics, Inc.
0.5334USD-2.40%Mkt Cap: 119.60M $P/E: —1d ago
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin…
Industry Peers
Biotechnology$128.08BUSDP/E 29.4
$78.44BUSD
$76.40BUSDP/E 18.4
$57.03BUSDP/E 37.3
$58.08BUSDP/E 35.4
$42.24BUSDP/E 18.0
$43.05BUSD
$41.41BUSDP/E 65.1
$32.80BUSDP/E 30.2
$30.03BUSDP/E 37.8
$25.10BUSD
$23.93BUSD
$22.99BUSDP/E 14.5
$22.27BUSDP/E 30.7
$22.54BUSDP/E 28.9
$22.22BUSD
$15.03BUSDP/E 17.5
$15.01BUSDP/E 15.8
$14.48BUSDP/E 18.4
$14.32BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
 Treasury yields rise as investors raise bets on Fed rate hike: AlphaCheck Stocks were down on Thursday as investors watched for stress signs in the bond market as long dated bond yields as oil prices remain elevated . | ||
 Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301 Tenaya Therapeutics (NASDAQ:TNYA) expects to provide regulatory and development updates in the fourth quarter for its two cardiac gene therapy programs and its small-molecule candidate TN-301, Chief Financial Officer Eric Hyllengren said during a Canaccord discussion. Hyllengren, who said he had be | ||